and the extracorporeal circulation, and the number of grafts bypassed. Serum matrix metalloproteinase‐9 reflected the occurrence of vein graft occlusion in subjects with no previous history of myocardial infarction. Serial Determinations of Serum Enzymes Following Aorta-Coronary Bypass Surgery. In the patients with myocardial infarction, this effect was not detected. Among the patients with no previous myocardial infarction, serum matrix metalloproteinase‐9 level was significantly higher in those with graft occlusion than in those without occlusion (54.0☑1.0 µg/L and 41.7☑0.4 µg/L, respectively, p = 0.006), and it correlated positively with the number of occluded grafts ( R = 0.55, p = 0.001). The study population consisted of 30 men with a history of myocardial infarction and 31 men without myocardial infarction who had undergone coronary artery bypass grafting.
We investigated whether the level of serum matrix metalloproteinase‐9 reflects its proposed role in occlusion of vein grafts. Matrix metalloproteinase‐9 has been suggested to have a role in graft occlusion ex vivo. Early occlusions are thought to be due to thrombosis or fibrointimal hyperplasia superimposed by thrombosis, but the etiology of these phenomena is not fully understood. The primary results after coronary artery bypass grafting are good, but early clinical events as a result of graft occlusion are still a problem.
0 kommentar(er)
